Jaime R Merchan

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Am J Clin Oncol 35:446-50. 2012
  2. ncbi request reprint Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model
    Jaime R Merchan
    Department of Oncology, Mayo College of Medicine, Rochester, MN 55905, USA
    J Natl Cancer Inst 98:756-64. 2006
  3. pmc Antiangiogenic activity of 2-deoxy-D-glucose
    Jaime R Merchan
    Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida, United States of America
    PLoS ONE 5:e13699. 2010
  4. pmc Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor
    Yuqi Jing
    Division of Hematology Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA
    Cancer Res 69:1459-68. 2009
  5. pmc Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects
    Yuqi Jing
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida 33136, USA
    Mol Cancer Res 10:1271-81. 2012
  6. pmc A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    BMC Cancer 12:199. 2012
  7. doi request reprint Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    N Engl J Med 369:722-31. 2013
  8. doi request reprint Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells
    Xiaoqi Wang
    Herbert Irving Comprehensive Cancer Center, Division of Hematology Oncology, Columbia University Medical Center, New York, New York, USA
    Mol Carcinog 52:218-28. 2013
  9. doi request reprint A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, Miller School of Medicine, University of Miami, Miami, FL Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore, Republic of Singapore
    Am J Clin Oncol 36:151-6. 2013
  10. ncbi request reprint Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, the Center for Study of the Tumor Microenvironment, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Int J Cancer 113:490-8. 2005

Research Grants

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Am J Clin Oncol 35:446-50. 2012
    ..Little progress has been made in the treatment of pancreatic cancer (PC). This study evaluated the clinical activity of gemcitabine, oxaliplatin, and cetuximab (GOC) in patients with locally advanced or metastatic PC...
  2. ncbi request reprint Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model
    Jaime R Merchan
    Department of Oncology, Mayo College of Medicine, Rochester, MN 55905, USA
    J Natl Cancer Inst 98:756-64. 2006
    ..Here we assessed the effects of plasminogen activator overexpression on tumor progression in a syngeneic mammary cancer model...
  3. pmc Antiangiogenic activity of 2-deoxy-D-glucose
    Jaime R Merchan
    Department of Medicine, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida, United States of America
    PLoS ONE 5:e13699. 2010
    ..Since glucose uptake and metabolism are increased to meet this energy need, the effects of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) on in vitro and in vivo angiogenesis were investigated...
  4. pmc Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor
    Yuqi Jing
    Division of Hematology Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA
    Cancer Res 69:1459-68. 2009
    ..This is the first retargeted oncolytic MV able to replicate in murine cells and target tumor vasculature in a uPAR-dependent manner...
  5. pmc Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects
    Yuqi Jing
    Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida 33136, USA
    Mol Cancer Res 10:1271-81. 2012
    ..Our studies uncover novel mechanisms of in vivo tumor control by modulation of the balance between tumor proteases and inhibitors, which may be exploited therapeutically...
  6. pmc A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
    BMC Cancer 12:199. 2012
    ..We investigated this combination as neoadjuvant therapy for locally advanced pancreatic cancer (LAPC)...
  7. doi request reprint Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    N Engl J Med 369:722-31. 2013
    ..This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy...
  8. doi request reprint Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells
    Xiaoqi Wang
    Herbert Irving Comprehensive Cancer Center, Division of Hematology Oncology, Columbia University Medical Center, New York, New York, USA
    Mol Carcinog 52:218-28. 2013
    ..Overall, our results suggest that combined HDACI and COX inhibition should be explored clinically to achieve more meaningful benefits from HDACI therapy in lung cancer...
  9. doi request reprint A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer
    Peter J Hosein
    Department of Medicine, Division of Hematology Oncology, Miller School of Medicine, University of Miami, Miami, FL Department of Oncology, Johns Hopkins Singapore International Medical Center, Singapore, Republic of Singapore
    Am J Clin Oncol 36:151-6. 2013
    ..This study was designed to determine the efficacy of nab-paclitaxel monotherapy in previously treated pancreatic cancer patients...
  10. ncbi request reprint Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition
    Jaime R Merchan
    Division of Hematology Oncology, Department of Medicine, the Center for Study of the Tumor Microenvironment, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Int J Cancer 113:490-8. 2005
    ..Low dose paclitaxel in combination with a Cox-2 inhibitor is an attractive antiangiogenic and antitumor strategy that deserves further evaluation in clinical trials...
  11. ncbi request reprint Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression
    Louay K Hallak
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 65:5292-300. 2005
    ..The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors...
  12. doi request reprint Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy
    Haibin Xi
    Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, 1550 NW 10th Avenue, Fox Building 406, Miami, FL 33136, USA
    Biochem Pharmacol 85:1463-77. 2013
    ..Taken together, our data support a model where under normoxia therapeutic (2-DG) and physiologic (GS) glucose restriction differentially activate autophagy, while under hypoxia they similarly inhibit it...
  13. ncbi request reprint A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Rochester, Minnesota, USA
    J Urol 174:1759-63; discussion 1763. 2005
    ..We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC)...
  14. ncbi request reprint Sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 295:2516-24. 2006
    ..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients...

Research Grants1

  1. Biomarkers for VEGF and mTOR Blockade in Advanced Renal Cancer
    Jaime Merchan; Fiscal Year: 2007
    ..This information will be extremely useful for the design of future trials using these agents in renal and other cancers and for future clinical practice. ..